본문으로 건너뛰기
← 뒤로

Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen.

2/5 보강
PET clinics 📖 저널 OA 0% 2022: 0/1 OA 2023: 0/2 OA 2024: 0/1 OA 2025: 0/1 OA 2026: 0/16 OA 2022~2026 2026 Prostate Cancer Treatment and Resear
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-30
OpenAlex 토픽 · Prostate Cancer Treatment and Research Immunotherapy and Immune Responses Estrogen and related hormone effects

Heidari P, Jadvar H, Kako B, Esfahani SA

📝 환자 설명용 한 줄

Prostate-specific membrane antigen (PSMA)-targeted theranostics have transformed prostate cancer management, but some tumors exhibit low or heterogeneous PSMA expression, limiting eligibility and effi

이 논문을 인용하기

↓ .bib ↓ .ris
APA Pedram Heidari, Hossein Jadvar, et al. (2026). Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen.. PET clinics. https://doi.org/10.1016/j.cpet.2026.02.003
MLA Pedram Heidari, et al.. "Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen.." PET clinics, 2026.
PMID 41951504 ↗

Abstract

Prostate-specific membrane antigen (PSMA)-targeted theranostics have transformed prostate cancer management, but some tumors exhibit low or heterogeneous PSMA expression, limiting eligibility and efficacy for radiopharmaceutical therapy. This review explores emerging biomarkers that may complement or expand beyond PSMA, including gastrin-releasing peptide receptor, fibroblast activation protein, prostate stem cell antigen, CD46, delta-like ligand 3, glypican-3, B7-H3, 6-transmembrane epithelial antigen of the prostate-1, trophoblast cell surface antigen-2, CEACAM5, and vicrostatin. We review their molecular biology, preclinical validation, clinical translation, and ongoing trials. These biomarkers represent diverse biological compartments, broadening the scope of precision radiotheranostics for prostate cancer.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반